"The tezepelumab data are clinically meaningful and offer patients with nasal polyps hope for a potential new treatment ...

Dupilumab was effective for patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) at 52 weeks.

The US Food and Drug Administration (FDA) has accepted a submission from GSK to review a new indication of Nucala ...

The co-primary endpoints were change from baseline in total nasal polyp size (measured by endoscopic ... tezepelumab’s potential as a new treatment for patients whose lives are disrupted by ...

What you may think are allergies or a cold, could be the sign of nasal polyps. Nasal polyps are non-cancerous growths that line the nasal passages and sinuses. They are soft, painless, and hang ...

The trial demonstrated patients treated with TEZSPIRE® (tezepelumab-ekko) had a statistically significant and clinically meaningful reduction in the size of nasal ... as a new treatment for ...

Dupixent is used as an add-on treatment for certain types of asthma ... Dupixent is used to treat chronic rhinosinusitis with nasal polyps in adults and children ages 12 years and older.

A new study published in the Ear, Nose and Throat Journal found that the severity of chronic rhinosinusitis with nasal ...

Patients with CRSwNP have a high burden of SCS use and associated health care costs, especially when they have comorbid asthma.

British drug maker GSK plc (GSK, GSK.L) announced Monday that the U.S. Food and Drug Administration has accepted for review, data ...

Nasal sinusitis, commonly called a sinus infection, is a condition characterised by inflammation or swelling of the tissue ...